According to the combined data, the level of fasting insulin after FMT therapy did not vary substantially from the level before therapy (WMD is equal to −1.06, 95 percent CI: −2.83~0.71, p is equal to 0.241; Figure 5), suggesting that patients suffering from obesity and related metabolic diseases may not benefit from FMT treatment in terms of fasting insulin levels. Here, INS is linked to obesity disorder.